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S_smary We have investigated the effects of H+-ATPase inhibitors, bafilomycin Al and 7-chloro-4-nitro-
benz-2-oxa-1,3 diazole (NBD), and the Golgi inhibitor, brefeldin A, on daunorubicin accumulation and
doxorubicin intracellular distribution in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-
L23 R. This cell line overexpresses a 190 kDa protein which is probably the product of the MRP gene and
shows an anthracycline accumulation defect and a drastically altered intracellular anthracycline distribution
from the parental cell line COR-L23/P. We found that all three agents could selectively increase the cellular
accumulation of daunorubicin in resistant cells. However, these effects were only seen at doses of the modifiers
which were equal to or greater than the IC50 of the modifier alone. Effects of the modifiers on the intracellular
distribution of doxorubicin fluorescence could, however, be seen at doses lower than those required to produce
significant effects on daunorubicin accumulation. However, when used in a continuous MTT chemosensitivity
assay none of the agents, used at maximum non-toxic doses, was able to sensitise COR-L23/R cells to
doxorubicin or to colchicine. Although these lead compounds are unlikely to be useful as clinical modifiers,
development of more selective analogues may prove useful in the modification of non-P-glycoprotein-mediated
multidrug resistance.
Acquired resistance of tumours to a group of structurally
and functionally unrelated cytotoxic drugs (multidrug resist-
ance, MDR) can be modelled in vitro by exposing tumour
cell lines to one of the group of drugs. Overexpression of a
170 kDa glycoprotein (P-glycoprotein, Pgp), acting as an
efflux pump in the plasma membrane, has been demonstrated
as a principal mechanism of MDR in many such cell lines
(Juranka et al., 1989). However, some MDR cell lines efflux
MDR drugs but do not overexpress the Pgp pump. An
example is the human large-cell lung carcinoma line COR-
L23/R, developed by stepwise increases in exposure to
doxorubicin (Twentyman et al., 1986), and resistant to doxo-
rubicin, daunorubicin, colchicine, vincristine and VP-16
(Coley et al., 1991). This cell line exhibits decreased intracel-
lular drug accumulation compared with the parental line,
with no detectable overexpression of Pgp or of mRNA from
the encoding mdrl gene (Barrand et al., 1990; Reeve et al.,
1990). A number of other such cell lines with similar patterns
of cross-resistance but lacking Pgp have also been described
(McGrath & Center, 1987; Mirski et al., 1987; Zijlstra et al.,
1987; Kuiper et al.. 1990).
A series of antisera to synthetic peptides from the deduced
sequence of Pgp were used to study a non-Pgp MDR human
leukaemia cell line (HL60,Adr) (Marquardt et al., 1990). One
of the antisera detected the presence of a 190 kDa membrane
protein in the resistant cells but not in the parental cells from
which they were derived. This antiserum (ASP-14) was also
used to identify a protein of the same size in our COR-L23/R
non-Pgp MDR line (Barrand et al., 1993). It now appears
probable that the 190 kDa protein band detected by anti-
serum ASP14 (and also by our own similar antiserum, CRA-
1) includes the product of the MRP gene, isolated and
sequenced from a non-Pgp-mediated human small-cell lung
cancer MDR subline H69/AR (Cole et al., 1992). The gene
sequence indicates that its product bears a close homology to
Pgp and is thus likely to play a role as an alternative
transporter in cells in which it is overexpressed. It has been
shown that compounds such as verapamil and cyclosporin A
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are highly effective modifiers of drug resistance in MDR cells
having overexpression of Pgp (Ford & Hait. 1990). The same
compounds, however, have relatively little effect in cells with
a non-Pgp-mediated MDR phenotype (Cole et al., 1989;
Barrand et al., 1993). It is therefore important to identify
other types of compounds which may be more effective as
resistance modifiers in cells showing non-Pgp-mediated
MDR.
Stnrking differences in intracellular distribution of
anthracyclines have been observed in HL60 Adr and COR-
L23,/R cells compared with their respective parental cells
(Marquardt & Center, 1992; Barrand et al., 1993; Coley et
al., 1993). Whereas intracellular fluorescence of drug is
mainly confined to the nucleus of COR-L23/P parental cells,
the most intensive fluorescence in COR-L23, R resistant cells
is seen in groups of perinuclear vesicles. Daunorubicin
initially enters the nucleus of HL60/Adr cells, and redistribu-
tion follows with efflux of drug from the nucleus of resistant
cells. Marquardt et al. (1990) have localised the 190 kDa
protein in HL60/Adr to the endoplasmic reticulum. They
have proposed a pathway of drug extrusion which involves
the concentration of anthracyclines into cytoplasmic vesicles
followed by an exocytotic process transporting the drug to
the exterior of the cell. This proposal is corroborated by
evidence that vacuolar H+-ATPase plays an important part
in the pathway of drug efflux from these cells (Marquardt &
Center, 1991).
We have, therefore, investigated the effect on drug
accumulation in our COR-L23,/R cell line of the inhibitors of
vacuolar H+-ATPases, bafilomycin Al and 7-chloro-4-
nitrobenz-2-oxa-1,3-diazole (NBD), which were reported to
restore drug accumulation in the HL60/Adr cells used in the
above-mentioned study (Marquardt & Center, 1991). We
have also examined the effects of the fungal antibiotic, bre-
feldin A, which has been identified as an inhibitor of protein
recycling from the endoplasmic reticulum into the Golgi
body (Lippincott-Schwartz et al.. 1989; Marquardt & Center,
1992). The effects of these compounds on the growth, intra-
cellular anthracycline distribution and accumulation and
chemosensitisation in COR-L23/P and COR-L23/R cell lines
are the focus of this study.
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Materals and medKods
Cell lines
The large cell lung carcinoma cell line COR-L23/P (Baillie-
Johnson et al., 1985) and MDR subine COR-L23/R were
derived in this laboratory. COR-L23/R was made drug resis-
tant by in vitro exposure to increasing doses of doxorubicin
(Twentyman et al., 1986) and is routinely maintained in
0.2 1tg ml-' (0.34JM) doxorubicin.
Culture conditions
The cell lines were grown as monolayers in RPMI-1640
medium plus 10% fetal calf serum (both from Gibco Biocult,
Paisley, UK). The medium was supplemented with penicillin
and streptomycin (I00Uml' and 100 Lgm ml rspectively)
(Gibco Biocult, Paisley, UK). Cell stocks were maintained in
75 cm2 tissue culture flasks (Falcon Plastics, Plymouth, UK)
in a humidified atmosphere of 8% carbon dioxide + 92% air
at 37C and were subcultured weekly.
Drugs
Stocks of doxorubicin (Farmitalia Carlo Erba, Milan, Italy)
(500 Lg ml' in water) were kept at -20C and dilutions
were made in PBS before addition to cells. Colchicine
(Sigma, Poole, UK) was dissolved in water and kept at
-20C. Solutions of brefeldin A [4-dihydroxy-2-(6-hydroxy-
l-heptenyl)-cyclopentanecrotonic acid lactone] and NBD
(7-chloro-4-nitrobenz-2-oxa-1,3-diazole) (Sigma, Poole, UK)
were freshly prepared in ethanol and diluted in RPMI-1640
growth medium before addition to cells. Bafilomycin A, (Pro-
fessor K. Altendorf, Universitat Osnabruck, Germany) was
dissolved in dimethylsulphoxide (DMSO) and diluted in
growth medium before addition to cells. [HJdaunorubicin
(specific activity 1.4Cimmol') was obtained from Amer-
sham International.
Drug response
The MTT assay used to determine drug sensitivity was based
on that described by Mosmann (1983) and modified in this
laboratory (Twentyman & Luscombe, 1987). COR-L23/P
and COR-L23/R cells were plated (200 id per well) into 96-
well microtitre plates (Falcon Plastics) at 5 x 103 and
10' cellsml-' repectively. For continuous drug exposure
experiments, plates were incubated (8% carbon dioxide, 92%
air, 37C) for 2 h and drugs or appropriate solvent controls
added in a volume of 20 p1. Plates were returned to the
incubator for a further 6 days, at which time the assay was
carried out. Plates for the 2 h drug exposure were incubated
for 24 h after plating. Drugs were then added as previously
and removed after 2 h followed by three rinses in warm
medium. Fresh medium was then added and the plates re-
turned to the incubator for a further 5 days before the assay
was performed. Appropriate solvent controls were used in all
experiments. After a total incubation of 6 days, 20i1 of
MTT (Sigma) (5mgml ' in PBS) was added to each well
and plates were returned to the incubator for 5 h. Medium
was then aspirated, 2001l of DMSO (BDH, Poole, UK)
added to each welL and the plates were agitated for 10 min
on a plate shaker. Opfical densities were read at 540 nm and
at a reference wavelength of 690am on a litertek Multiskan
MCC ELISA plate reader (Flow Laboratories, Rickmans-
worth, UK). Results are expressed as a fraction of control.
Quadruplicate wells were used at each dose point. IC50 values
(concentration ofagent to reduce final optical density to 50%
of control) were read by eye from dose-response curves.
The effects of brefeldin A (0.036gM), bafilomycin A,
(0.02tiM) and NBD (0.1I M) on the response of COR-L23/P
and COR-L23/R to doxorubicin and colchicine were
measured using a continuous 6 day MTI assay as above.
Cells were plated onto 96-well plates (as above) and
incubated for 2 h, followed by the addition of brefeldin A,
bafilomycin Al, or NBD, and, 1 h later, the addition of the
cytotoxics doxorubicin and colchicine. Plates were then
incubated and response assayed as described in the previous
section. The effect of brefeldin A (18gM) on the response of
COR-L23/P and COR-L23/R to doxorubicin for 2 h was
measured by plating cells out and 24 h later adding the
brefeldin A, followed 15 min later by the cytotoxic and
incubating for 2 h. Plates were then rinsed three times and
resuspended in warm medium, incubated for a further 5 days
and assayed as above.
Daunorubicin accumulation
COR-L23/P and COR-L23/R cells (4 x 104 and 6 x 10' res-
pectively) were plated in a volume of 2 ml of medium into
wells on six-well plates and incubated for 3 days so that the
cells were in the logarithmic phase of growth. Growth
medium was then aspirated and replaced with fresh medium
containing brefeldin A, bafilomycin A,, NBD or solvent con-
trol. The cells were then incubated for 15min before the
addition of 0.02 tg ml-' (0.04#LM) tritium-labelled dauno-
rubicin and a further incubation for 2 h. Medium was then
removed and cells were rinsed three times with ice-cold PBS
and lysed with I ml of 0.1% SDS. A 0.5 ml aliquot of this
solution was transferred into scintillation vials and mixed
with 5ml of Quicksafe A (Zinsser Analytic, Maidenhead,
UK). Radioactivity was measured over a period of 5 min on
a Beck-man LS5000CE. Cells from replicate wells were tryp-
sinised and counted using a haemocytometer in order that
results for accumulation could be expressed as drug content
per cell.
Intracellular doxorubicin distribution
Cells were plated onto sterile glass coverslips in 2 ml aliquots
in Falcon six-well plates at 5 x 10'ml-' and incubated over-
night (8% carbon dioxide, 92% air, at 3TC). The growth
medium was then removed and replaced with warm medium
containing bafilomycin Al, brefeldin A, NBD or the appro-
priate solvent. The coverslips were incubated for 15 min,
followed by the addition of doxorubicin at 10 ugml-'
(17 1JM) and further incubation for 2 h. Coverslips were
rinsed in ice-cold PBS, inverted onto slides and the edges
sealed with Glyceel (Gurr, BDH, Poole, UK) to protect
against dehydration. Intracellular doxorubicin fluorescence
was observed using the Biorad MRC-600 laserscan confocal
microscope (Biorad Lasersharp, Hemel Hempstead, UK)
using the 488 am laser line for excitation in the Biorad BHS
filters block, which allows detection of emitted light at all
wavelengths above 515 am. Images were collected and stored
on optical discs (Panasonic 470), allowing the measurement
ofpixel intensities within defined areas of the cells. Ratios of
fluorescence within the nucleus and within the cytoplasm
were calculated and used to indicate shifts of intracellular
drug distribution. Approximately 30 cells were measured for
each treatment point in an experiment.
Wbereas drug accumulation studies were carried out with
daunorubicin because of the ready availability of
radiolabelled compound at a reasonable price, we used doxo-
rubicin for confocal studies of intracellular distribution. The
reason for this choice is that measurement of nuclear/cyto-
plasmic fluorescent ratios is facilitated by a better-defined
nucleus for doxorubicin than for daunorubicin and because
differences between parent and resistant cells are greater for
the former anthracycline.
Results
Toxicity ofmodfiers alone
MiT assays were carried out in order to assess the toxicity
of brefeldin A, bafilomycin Al and NBD in the COR-L23/P
and COR-L23/R cell lines. Effects following different ex-
posure conditions were investigated, and the IC50 values are
shown in Table I. We used both short-term (i.e. 2 h)62 T. RHODES et al.
Table I Toxiciti- of compounds in COR-L"2 P and COR-L"2 R cell>
IC. A.ft
2 h etposure Continuous expoSure
Compound COR-L23 P COR-L23 R COR-L23 P COR-L23 R
Brefeldin A 34.3 3 9 0.092 C 130
(-.5) (11 6) (0069) (0 119)
Bafilomxcin A 3 539 0.029 0.03
(0.6) I0 OA X0 0000) I
NBD 28 66 11 'I1
(1.4) .) 0.1 0 5
V-alues represented are the means of three expenments. each in quadruplicate. >-ith
standard deviations in parentheses Assa% details are descnrbed in Mlaterial.S and
methods.
exposure (v-hich is similar to the conditions used in druz
accumulation and confocal microscopy expenments) and also
continuous drug exposure (for the duration of a 6 day assay).
No difference was observed between parent and resistant cells
follouwing treatment vvith brefeldin A and bafilomycin A.
IC4-, values for 2 h exposures were approximately 300-fold
greater than those in the continuous exposure assays for
brefeldin A and 120-fold greater for bafilomyncin A In con-
trast. COR-L23 R demonstrated a 2-fold resistance to NBD
compared u-ith the parental line in both 2 h and continuous
exposure assays. Furthermore. the differences betw-een IC,
values in 2 h and continuous exposure assays w-ere much
smaller than those for the other tu-o compounds (approxi-
mately 3-fold.) N-BD >-as thus much less potent in the
continuous exposure expenments than brefeldin A or bafilo-
m-cin A (12- to 16-fold and 38- to 66-fold respectively).
Based on these data and those in other published studies
(Marquardt & Center. 1991. 1992). w-e selected doses of
modifiers for investigation of their effects on drug accumula-
tion and distribution. Brefeldin A doses wvere chosen to be
below- and approaching the IC.-. for the accumulation studies
and about half the IC.. for distribution studies. similar to
doses (5pig ml-.. 18 wm( shou-n to inhibit Golgi recvcling in
previous studies (Lippincott-Schwartz et al.. 1989). Doses of
bafilomy-cin A- and N-BD for accumulation studies u-ere
selected to be both above and belou- the IC., (2 h) and to be
comparable u-ith doses used in a previous study (Marquandt
& Center. 1991 For dru2 distribution studies. the dose of
bafilom-cin A u-as close to the IC.-. u-hereas a ranze of
doses of NBD. similar to those in accumulation expenments.
uwas used.
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Cellular daunorulicLin accunmulation
The effects of the three compounds on [H]daunorubicin
accumulation in the parent and resistant cell lines u-ere
investigated and results are shou-n in Figure 1.
Incubation of COR-123 cells u-ith var-ing concentrations
of brefeldin A (FFigure la) produced slight. apparently dose-
dependent. increases in daunorubicin accumulation in both
parent and resistant cell lines. An increase u-as also seen for
the resistant cell line u-hen treated in combination u-ith
bafilomy-cin A (Fizure lb. and for both cell lines u-ith N-BD
(Fizure 1c). In all cases there u-as a selective effect on the
accumulation of [ H]daunorubicin in the resistant cell line
u-hich u-as particularly large for NBD at 100 pIm. This
resulted in a decrease in the differential accumulation
betu-een COR-L23 P and COR-L23 R. Howxever. accumula-
tion in COR-L"3 P u-as also significantl1 increased compared
u-ith its control.
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Intracellular doxorubicin di5tribution qualirarii e
Cells u-ere exposed to 10 Hag ml- 1O
-
m doxorubicin for 2 h
in the absence or presence of modifiers. Visualisation of
intracellular drug fluorescence in the parental cell line
demonstrated localisation in the nucleus with some diffuse
cytoplasmic fluorescence (Figure 2a). By contrast. in COR-
L23 R (Figure 2b) drug fluorescence was located in punctate
Figure I Accumulation of [-H]daunorubicin into COR-L23 P
)solid bars) and COR-L23 R (hatched bars) following exposure
to drug alone (Control) or to drug in the prescence of (a)
brefeldin A. )b) bafilom%-cin A- or (c) N-BD V'alues are the mean
from three separate expenments. tnplicate determinations being
obained from each Bars. s d Asten'sks indicate values siznfi-
cantl different from Control x-alues (unpaired Student t-test.
P<0.05).-MODIFICATION OF NON-Pgp MDR 63
Fugwe 2 Fluorescence distribution following 2 h incubation with doxorubicin (17ELM) in (a) COR-L23/P cdls or (b-g) COR-L23/R
cells. (a, b) doxorubicin alone, (c) doxorubicin plus brefeklin A (18j1M), (d) doxorubicin plus bafilomycin Al (4FM), (e) doxorubicin plus NBD (I pM), (f) doxorubicin plus NBD (10 M), (g) doxorubicin plus NBD (100ps).i4 T. RHODES et al.
areas of the cytoplasm, with low levels in the nucleus and
other cytoplasmnic areas as previously described (Barrand et
al., 1993; Coley et al., 1993). A shift of drug from cytoplas-
mic to nuclear regions was seen in the resistant cells when
treated with brefeldin A, (18 tiM) (Figure 2c) and bafilomycin
A, (411M) (Figure 2d), resulting in a distribution closer to
that in the parental control (Figure 2a) than the resistant
control (Figure 2b). Whole-cxll drug fluorescence was also
brighter in COR-L23/R when treated with brefeldin A
(18gM) (Figure 2c). A dose-dependent shift from cytoplasm
to nucleus was also observed with NBD, effects at 1, 10 and
100l M being shown in Figures 2e, 2f and 2g respectively.
However, overall cellular fluorescence was markedly in-
creased at the highest dose of NBD such that the cytoplasmic
fluorescence became almost equivalent to the nuclear
fluorescence.
Intracellular doxorubicin distribution (quantitative)
Intracellular doxorubicin fluorescence was quantified by
determining pixel intensity using an image analysis system.
The ratio of nuclear fluorescence to cytoplasmic fluorescence
is an indication of the drug distribution within a cell, and is
used to demonstrate quantitative shifts in fluorescence. For
each compound studied, there was considerable variation in
mean nuclear/cytoplamic ratios between individual experi-
ments (Table II). This was presumably due to some differ-
ences in the condition of the cells at the time of drug
exposure, although we did endeavour to control all known
variables. However, when ratios were relatively high in
parental (P) cells they also tended to be high in resistant (R)
cells (and vice versa). Hence the inter-experimental variation
in the P/R ratio was within acceptable limits.
In the parental cell line, the nuclear/cytoplasmic ratio was
not significantly altered by 18 JAM brefeldin A. It was, how-
ever, significantly reduced in two out of three experiments
with bafilomycin Al. In the case of NBD, alteration was only
seen at 100 lM and not at I or IOgIM. By contrast, in the
resistant cell line, highly significant changes in the nuclear/
cytoplasmic ratio were produced in all experiments with each
of the modifiers except NBD at the lowest dose studied
(1 ,sM). Clearly, therefore, each of the compounds does pro-
duce differential effects in the resistant line.
Examination of the P/R ratio (see footnote to Table II)
reveals that, in control groups, mean values were 3.4- to
3.6-fold higher in parent than in resistant cells. This ratio was
reduced to mean values of 2.1-fold for 18IM brefeldin A,
1.2-fold for 411M bafilomycin Al and 1.1- and 0.7-fold by 10
and l00>m NBD respectively.
Chemosensitisation
In continuous-exposure MTT assays (data not shown) max-
imum tolerated doses of modifiers (0.036tiM brefeldin A,
0.02 pM bafilomycin A,, and 0.1 FlM NBD) did not signifi-
cantly alter IC50 values for COR-L23/P or COR-L23/R
exposed to doxorubicin or colchicine. In 2 h exposure MTT
assays, two experiments were carried out with brefeldin A
and doxorubicin. Sensitisation ratios were 1.2 and 1.4 for
COR-L23/P and 1.7 and 2.3 for COR-L23/R.
Dicssiom
In view of the evidence that resistance modifiers such as
verapamil and cyclosporin A are relatively ineffective in cells
with a non-Pgp-mediated phenotype (Cole et al., 1989; Bar-
rand et al., 1993), it is important to identify other modifiers
with a selective action in such cells. An ideal modifier should
be able, at a concentration which is itself non-toxic, to
sensitise resistant cells to cytotoxic drugs while not changing
the response of the drug-sensitive population. It is against
these criteria that potential modifiers must be judged.
Previous studies have indicated that the non-Pgp-mediated
MDR cell line COR-L23/R distributes and extrudes drug
from the cell in a similar manner as the human leukaemia
cell line HL60/Adr (Marquard & Center, 1992; Barrand et
al., 1993). Both of these resistant cell lines overexpress a
Table k Nuclear/cytoplasmic ratios of doxorubicin fluorescence in cells treated with modifiers
before and during a 2 h doxorubicin exposure
Agent Dose Experimnt COR-L23/P COR-L23/R PIR*
A 1.15 (0.40) 0.27 (0.16) 4.26
Control B 1.63 (0.91) 0.72 (0.38) 2.26
Brefeldin A C 2.30 (1.71) 0.44 (0.35) 5.23
Brefeldin A ~~ ~~~~A 1.22 (0.44)a 0.52 (0.24fc 2.35
18AM B 1.65 (0.66)' 1.00 (0.55)C 1.65
C 2.18 (0.85)f 0.90 (0.62)c 2.42
A 0.97 (0.29) 0.27 (0.16) 3.59
Control B 1.77 (0.61) 0.62 (025) 2.86
C 2.95 (1.45) 0.70 (0.52) 4.21
Bafilomycin A, A 1.15 (0.44)a 0.57 (0.35) 2.02
41M B 1.52 (0.57)b 1.53 (0.73)C 0.99
C 1.90 (0.91)' 1.77 (0.76f 1.07
A 2.99 (2.35) 0.48 (0.34) 6.23
Control B 1.52 (0.50) 0.63 (0.36) 2.41
C 2.19 (1.02) 0.73 (0.54) 3.00
A 2.70 (0.94f 0.55 (0.29f 4.91
1 ILM B 1.44 (0.51 0.71 (0.30r 2.03
NBD C 2.20 (1.Ol) 0.63 (0.71f 3.49
A 1.73 (0.47)b 2.48 (1.72)' 0.70
10IM B 1.61 (0.98) 1.92 (0.70)' 0.84
C 2.64 (1.91r) 1.53 (0.74)' 1.73
A 0.85 (0.32)' 1.39 (0.36)' 0.61
IOO1 M B 0.92 (0.47)T 1.41 (0.51)' 0.65
C 1.09 (0.73)' 1.48 (0.67)T 0.74
Data are means from three independent experiments each with measurements from 30 different
cells (standard deviations in parentheses). Control groups are cells incubated in the presence of the
appropriate solvent. 'Not significantly different (P >0.05) from control groups within same
experiment. (A, B or C). bSignificantly different (0.01 <P<0.05) from control groups within same
experiment (A, B or C). 'Highly significantly different (P <0.01) from control groups within same
experiment (A, B or C). *P/R = (nuclear/cytoplasmic ratio in COR-L23/P) divided by
nuclear/cytoplasmic ratio in COR/L23/R).MODIFICATION OF NON-Pgp MDR 65
190 kDa protein disinct from Pgp. Intracellular drug distri-
bution was studied for HL60/AR (a imilar subline to HL60/
Adr) and COR-L23/R using laser-assisted confocal
microscopy, and both were found to accumulate anthracy-
clines in cytoplamic vesicles (Hindenburg et al., 1989; Bar-
rand et al., 1993; Coley et al., 1992). Marquardt and Center
(1992) suggested a mechanism for drug extrusion from their
non-Pgp HL60/Adr cell line which involves intracellular
vesicular transport. With this mechanism in mind, we have
investigated the effects of compounds which interrupt
vesicular transport on the drug distribution within resistant
and sensitive cells. Both bafilomycin Al and NBD have been
shown to increase whole-cell drug accumulation in the HL60/
Adr cell line (Marquandt & Center, 1991), whereas the Golgi
recycling inhibitor brefeldin A did not alter drug accumula-
tion in the same cell line (Marquardt & Center, 1992).
Toxicity of brefeldin A to COR-L23/P and COR-L23/R
cell lines had been investigated previously (Workman &
Twentyman, 1991), and no differential was observed between
parental and resistant cell ines. Our study agrees with those
findings. IC^o values were considerably greater for short-term
exposures than for long-term exposures, and this was also
true for bafilomycin Al. However, in contrast, cells were
generally much more resistant to NBD in continuous-
exposure experiments than the other agents. The difference
between continuous exposure and short-term exposure for
this compound was very smalL and therefore it may be
conluded that the compound either has a very short half-life
or is, in some other way, self-limiting. Also, COR-L23/R
cells are 2-fold resistant to NBD cmpared with COR-L23/P
sensitive cells. These toxicity data facilitate the distinction
between alterations in drug accumulation and distnbution
which may be due to specific effects upon vesicular tansport
or H+-ATPase activity or merely due to non-specific toxicity
of the agent.
Marquardt and Center (1991) in their investigations found
that bafilomycin A1 (4.41M) had no effect on the dauno-
rubicin accumulation in parental lines but dramatically in-
cased drug accumulation in resistant cell lines. Although
accumulation was increased to a greater extent in HL60/Vinc
(vinristne resistant), which expresses Pgp, than in HL60/
Adr, bafilomycin A1 did not compete with p[H)azidopine
binding to Pgp, and it was therefore concluded that the
inhibition of efflux was due to an inhibition of H+-ATPase
activity. Also, NBD (100LM) increased drug accumulation
and inhibited drug efflux in HL60/Vinc and HL60/Adr. How-
ever, toxicity data for these compounds in the HL60 cell lines
were not presented and it is therefore impossible to interpret
these data in mechanistic terms.
In our study both the Golgi inhibitor brefeldin A and the
H+-ATPase inhibitors bafilomycin A1 and NBD increased, in
a dose-dependent manner, the [HJdaunorubicin accumula-
tion in COR-L23/R at doses which had little effect on the
accumulation in the drug-sensitive parental line COR-L23/P.
However, only the highest dose (100IM) of NBD brought
the drug content in the resistant cell line COR-L23/R to
levels equal to those in the parental line. These increases
were, however, statistically significant only for brefeldin A at
36 lM (although close to signifiance at 18gM) in COR-L23/
R, bafilomycin Al in COR-L23/R at I0LM but not at 41M
and NBD for both the parent and resistant lines at 100pM.
Effects of increasig drug accumulation in restant ines by
both brefeldin A and bafilomycin Al were therefore only
seen at doses close to the ICQ valus for these agents (i.e.
38.9 M and 3.9 m re ). Similarly, 100JM NBD is
many times higher than the IC50 for this agent alone. It is
therefore impossible to distinguish from these data between a
specific effect on the drug efflux mechanism operative in
COR-L23/R and circumvention of this mechanism by non-
specific membrane damage.
The assessent of whole-cell drug accumulation may not
reveal changes which occur on an intracellular level in drug
distributon between different compartments in parental and
resistant cells. Following treatment with these compounds,
the visualsation of intracellular drug fluorescence in COR-
L23/P and COR-L23/R by laser-scan confocal microscopy
allows the shift of doxorubicin distribution to be observed.
Our results show that each of the compounds studied can
modify the distribution in the resistant cells towards that seen
in parental cells, although the greatest effects on intracellular
distribution are again only seen at doses of modifiers which
are themselves toxic.
Quantitation of intracellular drug fluorescence can be
achieved by image analysis in conjunction with confocal
microscopy. Using such analysis we have found that brefel-
din A (18JM) significntly shifts doxorubicin fluorescence
from the cytoplasm to the nucleus in the reistant cell line,
with no signiit changes to the parental line. Bafilomycin
Al produced changes in intracellular doxorubicin distribution
at a dose which did not greatly increase daunorubicin cellular
accumulation. However, distribution was also sigificntly
altered in the parent lne by this agent. A dose of 10I1M
NBD signifintly altered distribution in the reistant but not
the parental line. It is possible, therefore, to observe shifts of
doxorubicin fluorescence within the cell, towards the nucleus,
at modifer doses which do not produce dramatic changes in
cellular drug accumulation of daunorubicin. It seems likely
therefore that the measurement of effects on intracellular
drug distribution will constitute an important aspect in the
development of modifirs for non-Pgp MDR.
Despite the activity of these compounds as modifiers of
drug distribution, the cytotoxic concentrations required to
achieve any effect only allowed for investigation of sensitisa-
tion under these conditions with brefeldin A, where only
minimal selective sensitisation was observed. There was no
sensitisation at the doses used for continuous exposure
experiments as would be expected for a potent modifier. The
compounds in this study were chosen as potential modifies
of non-Pgp MDR with alternative methods of action to the
traditional Pgp-binding compounds. Marquardt and Center
(1991) postulated a H+-ATPase inhibitory effect of
bafilomycin A1 and NBD, which reversed the accumulation
deficit in both the Pgp- and non-Pgp-containing cell lines in
their study. Any effect of brefeldin A may be related to its
function as a Golgi inhibitor (Lippincot-Schwartz et al.,
1989). However, the compounds were no better than the
standard Pgp chemosensitisers cyclosporin A, PSC-833 and
verapamil (Barfand et al., 1993); in fact, verapamil is the
most active of these agents in reversing the accumulation
deficit. Clearly, none of the compounds reported so far as
non-Pgp modifiers shows the large differential effects that are
seen when compounds such as cyclosponn A and PSC-833
are used to sensitise Pgp-expressing cell lines.
The data which we have presented indicate that the three
compounds which we have studied are unlikely to be useful
as potential clinial modifiers. The results, however, are
sufficiently positive that further investigation of related com-
pounds with possibly improved therapeutic indices may be
worthwhile.
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